Abstract | PURPOSE: METHODS: An open-label, 12-week, 2-center study was conducted. Thirty-seven patients with treatment-naïve NTG received DTFC for 12 weeks to reduce IOP. Primary outcome measures were changes in IOP from baseline to 12 weeks of treatment at a peak drug effect. Secondary outcome measures were changes in IOP from baseline to 12 weeks of treatment a trough drug effect and 8 hours after drug administration. At each visit, IOP was measured at 9 AM and then DTFC was administered by a hospital personnel. IOP was also measured at 11 AM and 5 PM At week 12, the IOP was measured at 1 and 3 PM as well. RESULTS: The IOP at peak drug effect (11 AM) at 12 weeks was significantly reduced to 11.9±2.6 mm Hg from the baseline of 15.6±2.5 mm Hg (23.7%, P<0.0001). Significant reduction in the IOP was also achieved at trough drug effect (9 AM) and at 8 hours after drug administration (5 PM) at 12 weeks (20.5% and 24.4%, respectively, all P<0.0001). Eye irritation (59.5%) was the most frequently reported adverse event followed by ocular hyperemia (16.2%). The majority of eye irritations were mild in intensity. No patients discontinued the DTFC due to an adverse event and no systemic adverse event was considered related to study medication. CONCLUSIONS: DTFC is a safe and effective IOP-lowering agent in patients with NTG.
|
Authors | Tae-Woo Kim, Martha Kim, Eun Ji Lee, Jin Wook Jeoung, Ki Ho Park |
Journal | Journal of glaucoma
(J Glaucoma)
2014 Jun-Jul
Vol. 23
Issue 5
Pg. 329-32
ISSN: 1536-481X [Electronic] United States |
PMID | 23377586
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antihypertensive Agents
- Drug Combinations
- Sulfonamides
- Thiophenes
- dorzolamide-timolol combination
- Timolol
|
Topics |
- Antihypertensive Agents
(adverse effects, therapeutic use)
- Drug Combinations
- Female
- Humans
- Intraocular Pressure
(drug effects)
- Low Tension Glaucoma
(diagnosis, drug therapy)
- Male
- Middle Aged
- Prospective Studies
- Sulfonamides
(adverse effects, therapeutic use)
- Thiophenes
(adverse effects, therapeutic use)
- Timolol
(adverse effects, therapeutic use)
- Tonometry, Ocular
- Visual Acuity
(physiology)
- Visual Field Tests
|